

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 31/64, 31/44, 31/155 // (A61K 31/64, 31:44, 31:155)</b>		A1	(11) International Publication Number: <b>WO 99/03477</b> (43) International Publication Date: <b>28 January 1999 (28.01.99)</b>
(21) International Application Number: <b>PCT/GB98/02110</b> (22) International Filing Date: <b>16 July 1998 (16.07.98)</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: <b>9715295.3 18 July 1997 (18.07.97) GB</b>		Published <i>With international search report.</i>	
(71) Applicant ( <i>for all designated States except US</i> ): <b>SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</b>			
(72) Inventors; and (75) Inventors/Applicants ( <i>for US only</i> ): <b>BUCKINGHAM, Robin, Edwin [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). SMITH, Stephen, Alisair [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Beecham Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).</b>			
(74) Agent: <b>RUTTER, Keith; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</b>			
(54) Title: <b>TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND DIGUANIDE</b>			
(57) Abstract			
<p>A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent, to a mammal in need thereof; and composition for use in such method.</p>			